Clinical trials: Premature Baby 26 to 32 Weeks, open to volunteers
Intestinal Malabsorption
Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants<3rd percentile* born at 26-32 weeks GA.
- Trial name
- NCT05904626
- Testing
- ELGN-2112
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Elgan Pharma Ltd.
Premature - Weight 1000g-2499g or Gestation of 28-37weeks, Premature Baby 26 to 32 Weeks
Comparison of Two Early Treatments for Premature Babies and Their Effects Over Time
According to the latest World Health Organization report, prematurity is a major health issue, recognized as a significant vulnerability factor contributing to the emergence of neurodevelopmental disorders.
- Conditions
- Premature - Weight 1000g-2499g or Gestation of 28-37weeks, Premature Baby 26 to 32 Weeks, Premature Baby 33 to 36 Weeks, Premature Between 32 and 36 Weeks of Amenorrhoea
- Trial name
- PREMOTSENS (NCT07261046)
- Testing
- ATVV (Auditory, Tactile, Visual and Vestibular stimulation), Singing
- Where
- 2 sites in France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Elsan